Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Behzad Aghazadeh purchased 2,383,333 shares of Scribe Therapeutics stock in a transaction dated Friday, July 24th. The stock was bought at an average cost of $15.15 per share, with a total value of $36,107,494.95. Following the completion of the transaction, the director owned 3,080,983 shares in the company, valued at approximately $46,676,892.45. This represents a 341.62% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.
Behzad Aghazadeh also recently made the following trade(s):
- On Tuesday, July 28th, Behzad Aghazadeh acquired 7,905 shares of Scribe Therapeutics stock. The shares were bought at an average cost of $18.25 per share, for a total transaction of $144,266.25.
Scribe Therapeutics Stock Performance
SCTX opened at $18.06 on Wednesday. Scribe Therapeutics Inc. has a 1 year low of $17.31 and a 1 year high of $25.49.
Featured Articles
- Five stocks we like better than Scribe Therapeutics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
